Amgen has initiated a large-scale voluntary recall of more than 944,000 bottles of its heart and kidney medications distributed across the United States. As a result of the discovery of a foreign substance on the surface of some tablets and the identification of manufacturing inconsistencies, the recall is a proactive measure to ensure consumer safety even though no illnesses or injuries have been reported.
Key takeaways
- More than 944,000 units of medicine were withdrawn nationwide.
- Affected medications include Corlanor, used to treat heart failure, and Sensipar, used for kidney health.
- The FDA has classified this as a Class II recall, indicating a low likelihood of serious adverse health effects.
- No consumer complaints or medical incidents have been linked to this recall.
Understand the recall
The US Food and Drug Administration (FDA) announced He remembers After discovering the presence of a foreign substance on the outer coating of tablets in selected batches. This issue has been identified in a specific packaging area within an Amgen facility. Furthermore, some batches were found to have deviated from Current Good Manufacturing Practice (CGMP) standards, which could affect the safety and effectiveness of the drug.
Affected medications
The recall includes several presentations for Corlanor (ivabradine) and Sensipar (cinacalcet). Affected inventory includes different tablet strengths processed in specific packaging environments. Patients are encouraged to refer their medication bottles to the specific lot codes and expiration dates listed on the official FDA recall notice.
| medicine | power |
|---|---|
| Corlanor (ivabradine) | 5 mg |
| Corlanor (ivabradine) | 7.5 mg |
| Sensipar (cinacalcet) | 30 mg |
| Sensipar (cinacalcet) | 60 mg |
| Sensipar (cinacalcet) | 90 mg |
Safety assessment and next steps
While the FDA has classified this as a Class II recall — meaning there is a remote risk of serious consequences and the potential for temporary, reversible health problems — the overall risk to patient safety is currently assessed as low. Amgen has confirmed that external assessments do not currently indicate any direct threat to users.
Patients who find that their medications are included in the recall should not stop their treatment suddenly, as this could lead to adverse heart or kidney disease outcomes. Instead, consult the doctor or pharmacist who prescribed the medicine immediately to check the safety of your supply and arrange for a refund or replacement of the bottle.
